When was Terns Pharma founded?
Terns Pharmaceuticals, Inc. was officially founded in 2016 by a team of seasoned biopharmaceutical executives and life science entrepreneurs. Headquartered in California, the clinical-stage biopharmaceutical enterprise set out to develop a robust portfolio of small-molecule drug candidates targeting serious oncological conditions, non-alcoholic steatohepatitis, and obesity. The company advanced its specialized therapeutic pipelines through rigorous international clinical trials before successfully completing its initial public offering on the NASDAQ market in early 2021.
Related FAQs
Terns Pharmaceuticals, Inc.
Investing in pharmaceutical equities offers defensive characteristics, steady cash flows, and exposure to breakthrough medical innovations such as oncology treatments and metabolic disease therapies.
Merck KGaA (the prominent German science and technology enterprise) expanded its specialty pharmaceutical and bioprocessing pipeline by completing the strategic acquisition of SpringWorks Therapeutics, a commercial-stage biopharmaceutical company foc...
Merck entered into a definitive agreement to acquire Terns Pharmaceuticals in an all-cash transaction valued at approximately $6.7 billion.
Terns Pharmaceuticals, trading under the ticker symbol TERN, is a clinical-stage biopharmaceutical enterprise focused on developing treatments for oncology and chronic disease conditions.
Terns Pharmaceuticals, Inc.
Financial analysts covering Terns Pharmaceuticals, Inc. (NASDAQ: TERN) maintain consensus 12-month average price targets that underscore the high-growth, high-risk profile characteristic of clinical-stage biopharmaceutical enterprises.
Merck & Co. is an entirely independent, publicly traded American multinational pharmaceutical corporation listed on the New York Stock Exchange and is not owned by Bayer.
Tern plc, traded on the London Stock Exchange under the ticker TERN, belongs to the Technology sector.
Terumo Corporation operates with a massive global workforce of approximately thirty thousand five hundred ninety-one consolidated associates, functioning as a world-leading medical technology company.
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical enterprise dedicated to discovering and developing an innovative portfolio of small-molecule product candidates targeting serious oncological diseases and metabolic conditions.
Tern PLC (AIM: TERN), an investment company specializing in the Internet of Things (IoT) technology sector, maintains a public market capitalization valuation fluctuating around 10.6 million British Pounds (roughly 1.
Yes, Pacific Western Bank and Banc of California completed a transformational merger on December 1, 2023.
Terns Pharmaceuticals, Inc. officially completed its initial public offering and began trading its common stock on the NASDAQ Global Market under the ticker symbol TERN on February 5, 2021.